Efficacy and tolerability of oral lacosamide as adjunctive therapy in pediatric patients with pharmacoresistant focal epilepsy

Gavatha, Marina; Ioannou, Ioannis; Papavasiliou, Antigoni

doi:10.1016/j.yebeh.2011.02.005

Cited by 52 publications

(67 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Unauthorised copying and distribution is prohibited. + [33] + [34] + [35] + [36,37] + [38] Insomnia + [39] + [40] + [41][42][43] Somnolence + [39] + [30,31] + [40] + [32] + [33,44,45] + [46] + [34,47,48] + [41][42][43] + [35] + [36,49] + [50] Sedation + [51] Concentration problems + [36] Aphasia/dysarthria…”

Section: Most Frequent Dose-related Adverse Effects To Antiepileptic mentioning

confidence: 99%

“…+ [52] Depression + [31] + [53] + [52,54] Suicidal ideation + [53] Behavioural problems + [39,55] + [30,56] + [51,57] + [40] + [32,58] + [59,60] + [45] + [46] + [41][42][43] + [35] + [36,37,49,52] + [38,50] Hallucinations/psychosis + [37] Blurred vision/visual field deficits + [51,63] + [53] Diplopia/eye movement abnormalities…”

Section: Most Frequent Dose-related Adverse Effects To Antiepileptic mentioning

confidence: 99%

“…[85] Alternatively, electrophilic metabolites can react with nucleophilic groups on proteins without covalent binding. [86] The drug-peptide + [50] Haematological abnormalities + [40] MRI abnormalities + [72][73][74] a The list is assembled by anatomophysiological systems (CNS, gastrointestinal system, skin, and renal system). This material is the copyright of the original publisher.…”

Section: Idiosyncratic Adverse Effectsmentioning

confidence: 99%

See 2 more Smart Citations

Safety and Tolerability of Antiepileptic Drug Treatment in Children with Epilepsy

et al. 2012

View full text Add to dashboard Cite

Section: Most Frequent Dose-related Adverse Effects To Antiepileptic mentioning

confidence: 99%

Section: Most Frequent Dose-related Adverse Effects To Antiepileptic mentioning

confidence: 99%

Section: Idiosyncratic Adverse Effectsmentioning

confidence: 99%

See 1 more Smart Citation

Safety and Tolerability of Antiepileptic Drug Treatment in Children with Epilepsy

et al. 2012

View full text Add to dashboard Cite

“…[ [3][4][7][8][9] The most reported adverse events were mild to moderate and were more commonly observed during the titration phase. The most common adverse events were related to CNS and gastrointestinal side effects, and they appeared to be dose related.…”

Section: Discussionmentioning

confidence: 99%

“…The experience is limited and only there are a few case reports and retrospective data on use of lacosamide in children in the last few years. [3][4] We here report a five year old girl who developed significant hyperactivity as a side effect of lacosamide that persisted for one month till the drug was used and then reverted after it was stopped. This side effect has not been reported in adults and has not been emphasized in the limited literature available on use of lacosamide in children.…”

Section: Introductionmentioning

confidence: 88%

‘Reversible Inattention and hyperactivity in a child on Lacosamide - In south Indian Subpopulation’

Pasha¹,

Kamate²,

Suresh³

2014

IOSRJPBS

View full text Add to dashboard Cite

show abstract

Use of Real‐World Data and Pharmacometric Modeling in Support of Lacosamide Dosing in Pediatric Patients Under 4 Years of Age

Lukka

Woods

Chhim

et al. 2021

The Journal of Clinical Pharma

View full text Add to dashboard Cite

The antiepileptic drug lacosamide (LCM) is approved in the United States and the European Union as monotherapy as well as adjunctive therapy for the treatment of focal seizures in children ≥4 years of age and adults. Using real‐world therapeutic drug monitoring data, we performed a pharmacometric analysis for 315 pediatric patients (>1 month to <18 years of age) who received lacosamide as both monotherapy and adjunctive therapy. Population pharmacokinetic modeling was performed using nonlinear mixed‐effects modeling with a 1‐compartment structural model with linear elimination, where clearance and volume of distribution were allometrically scaled for body weight, with no further need for age‐associated maturation functions. A covariate analysis for age, sex, race, and coadministration of other antiepileptic drugs identified phenobarbital and felbamate to significantly increase lacosamide clearance (1.71‐ and 1.46‐fold, respectively). Based on the developed population pharmacokinetic model, simulations were performed in virtual pediatric patients to explore age‐associated dose requirements to match lacosamide exposure in patient groups of different age with the exposure achieved in children ≥4 year of age with the weight‐based dosing recommendations provided by the US Food and Drug Administration. Based on this approach, our analysis suggested that children ≥3 years of age needed the same dose as recommended by the US Food and Drug Administration for children ≥4 years of age (12 mg/kg/d), while children 1 to 3 years of age may need 13 to 14 mg/kg/d and infants between 1 month and 1 year of age may need 15 to 18 mg/kg/d (based on their actual age) to match the exposure seen in children ≥4 years of age.

show abstract

Efficacy and tolerability of oral lacosamide as adjunctive therapy in pediatric patients with pharmacoresistant focal epilepsy

Cited by 52 publications

References 15 publications

Safety and Tolerability of Antiepileptic Drug Treatment in Children with Epilepsy

Safety and Tolerability of Antiepileptic Drug Treatment in Children with Epilepsy

‘Reversible Inattention and hyperactivity in a child on Lacosamide - In south Indian Subpopulation’

Use of Real‐World Data and Pharmacometric Modeling in Support of Lacosamide Dosing in Pediatric Patients Under 4 Years of Age

Contact Info

Product

Resources

About